Oncopeptides AB
The answer first
Does Oncopeptides beat the market?
No, Oncopeptides has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 5% of Nordic stocks
- Quality28
- Value2
- Trend37
No. 175 of 195 in healthcare
Max for seven days
Follow Oncopeptides with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Oncopeptides
Your first answer is free, no account needed.
Do you own Oncopeptides, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Oncopeptides and a few more. Free, no card.
Super Stock+44.6%In short
- Oncopeptides has fallen 65.1% over the past year, including dividends.
- Overall, Oncopeptides ranks better than 5% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 97.4%. The price is 98.7% below its peak now.
What do analysts think of Oncopeptides?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 5% of Nordic stocks.
No. 175 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 160 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity−8.45
- Asset turnoverSales divided by everything the company owns0.59
- Return on equityProfit divided by equity−287.9%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 182 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equitynegative earnings
- P/SPrice divided by sales5.9
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 90 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+0.3%
- 6 months−2.4%
- 9 months+4.8%
- 12 months−65.1%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Oncopeptides
5 funds we follow own Oncopeptides. The share is how much of the fund the stock makes up.
- Sweden5
From the funds' latest known holdings.
About Oncopeptides
Oncopeptides AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 71 employees.
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for with an alkylating payload, developed for the treatment of adult patients with multiple myeloma. The company's PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells.


See the full analysis of Oncopeptides.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card